M. Kathleen Behrens - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Director
Signature
/s/ M. Kathleen Behrens
Issuer symbol
IGMS
Transactions as of
14 Aug 2025
Net transactions value
$0
Form type
4
Filing time
14 Aug 2025, 17:17:32 UTC
Previous filing
02 Jul 2025
Next filing
29 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BEHRENS M KATHLEEN Director C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW /s/ M. Kathleen Behrens 14 Aug 2025 0001211701

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Disposed to Issuer -22,222 -100% 0 14 Aug 2025 Direct F1
transaction IGMS Common Stock Disposed to Issuer -330,700 -100% 0 14 Aug 2025 See footnote F1, F2
transaction IGMS Common Stock Disposed to Issuer -29,807 -100% 0 14 Aug 2025 See footnote F1, F3
transaction IGMS Common Stock Disposed to Issuer -29,806 -100% 0 14 Aug 2025 See footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

M. Kathleen Behrens is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.
F2 Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee.
F3 Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
F4 Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.